JW Pharmaceutical Corp (001067) - Total Liabilities

Latest as of September 2025: ₩257.46 Billion KRW ≈ $174.47 Million USD

Based on the latest financial reports, JW Pharmaceutical Corp (001067) has total liabilities worth ₩257.46 Billion KRW (≈ $174.47 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

JW Pharmaceutical Corp - Total Liabilities Trend (2014–2024)

This chart illustrates how JW Pharmaceutical Corp's total liabilities have evolved over time, based on quarterly financial data. See how liquid is JW Pharmaceutical Corp's working capital to evaluate short-term liquidity relative to the company's equity base.

JW Pharmaceutical Corp Competitors by Total Liabilities

The table below lists competitors of JW Pharmaceutical Corp ranked by their total liabilities.

Company Country Total Liabilities
TESGAS S.A.
WAR:TSG
Poland zł29.02 Million
Starhedge SA
WAR:SHG
Poland zł8.79 Million
Gayatri Highways Limited
NSE:GAYAHWS
India Rs16.12 Billion
Seraphim Space Investment Trust PLC
LSE:SSIT
UK GBX16.86 Million
Horisont Energi AS
OL:HRGI
Norway Nkr7.09 Million
UNIDOC HEALTH CORP.
F:L7T
Germany €2.33 Million
JLT Mobile Computers AB (publ)
ST:JLT
Sweden Skr29.90 Million
Kontigo Care AB
ST:KONT
Sweden Skr13.13 Million

Liability Composition Analysis (2014–2024)

This chart breaks down JW Pharmaceutical Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see JW Pharmaceutical Corp stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.51 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.73 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.42 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how JW Pharmaceutical Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for JW Pharmaceutical Corp (2014–2024)

The table below shows the annual total liabilities of JW Pharmaceutical Corp from 2014 to 2024.

Year Total Liabilities Change
2024-12-31 ₩275.11 Billion
≈ $186.44 Million
-27.53%
2023-12-31 ₩379.60 Billion
≈ $257.25 Million
-5.62%
2022-12-31 ₩402.21 Billion
≈ $272.57 Million
-9.52%
2021-12-31 ₩444.51 Billion
≈ $301.24 Million
+30.12%
2020-12-31 ₩341.62 Billion
≈ $231.51 Million
-0.44%
2019-12-31 ₩343.12 Billion
≈ $232.52 Million
+2.83%
2018-12-31 ₩333.68 Billion
≈ $226.13 Million
-7.34%
2017-12-31 ₩360.10 Billion
≈ $244.03 Million
-3.91%
2016-12-31 ₩374.76 Billion
≈ $253.97 Million
-3.43%
2015-12-31 ₩388.07 Billion
≈ $262.99 Million
+5.11%
2014-12-31 ₩369.22 Billion
≈ $250.21 Million
--

About JW Pharmaceutical Corp

KO:001067 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$5.74 Million
₩8.48 Billion KRW
Market Cap Rank
#28306 Global
#2010 in Korea
Share Price
₩41000.00
Change (1 day)
+0.00%
52-Week Range
₩41000.00 - ₩65600.00
All Time High
₩131401.16
About

JW Pharmaceutical Corporation manufactures and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cancer, immunological disease, cardiovascular system and metabolic diseases, regenerative medicine, eye diseases , and pancreatic cancer. The company also offers infant care system, gynecological examining table, operating room equipment, steam steri… Read more